NCT02906176View on ClinicalTrials.gov

Influence of SLCO2B1 Polymorphism on the PK of Voriconazole in CYP2C19 PM

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

September 30, 2016

Primary Completion Date

November 30, 2016

Study Completion Date

January 31, 2017

Conditions
Healthy Volunteers
Interventions
DRUG

Vfend (voriconazole) intravenous infusion

Vfend (voriconazole) 200 mg intravenous infusion during 1.5 h

DRUG

Vfend (voriconazole) tablet

Vfend (voriconazole) 200 mg tablet once

Trial Locations (1)

Unknown

Seoul National University Hospital Clinical Trial Center, Seoul

All Listed Sponsors
lead

Seoul National University Hospital

OTHER

NCT02906176 - Influence of SLCO2B1 Polymorphism on the PK of Voriconazole in CYP2C19 PM | Biotech Hunter | Biotech Hunter